Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10:e1001547.
World Health Organization (WHO). Depression – fact sheet. https://www.who.int/news-room/fact-sheets/detail/depression. Accessed 3 Mar 2019.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.
Mauskopf JA, Simon GE, Kalsekar A, Nimsch C, Dunayevich E, Cameron A. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety. 2009;26:83–97.
Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv. 2014;65:977–87.
Carney RM, Freedland KE. Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiatry. 2009;166:410–7.
Fekadu A, Rane LJ, Wooderson SC, Markopoulou K, Poon L, Cleare AJ. Prediction of longer-term outcome of treatment-resistant depression in tertiary care. Br J Psychiatry. 2012;201:369–75.
Lepine BA, Moreno RA, Campos RN, Couttolenc BF. Treatment-resistant depression increases health costs and resource utilization. Braz J Psychiatry. 2012;34:379–88.
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–4.
Han Y, Chen J, Zou D, Zheng P, Li Q, Wang H, et al. Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat. 2016;12:2859–67.
Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016;46:1459–72.
Aan het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012;72:537–47.
Aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139–45.
Cusin C, Ionescu DF, Pavone KJ, Akeju O, Cassano P, Taylor N, et al. Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation. Aust N Z J Psychiatry. 2017;51:55–64.
Vande Voort JL, Morgan RJ, Kung S, Rasmussen KG, Rico J, Palmer BA, et al. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord. 2016;206:300–4.
Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5:65–78.
Schoevers RA, Chaves TV, Balukova SM, Aan het Rot M, Kortekaas R. Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry. 2016;208:108–13.
Rosenblat JD, Carvalho AF, Li M, Lee Y, Subramanieapillai M, McIntyre RS. Oral Ketamine for Depression: A Systematic Review. J Clin Psychiatry. 2019;80. https://doi.org/10.4088/JCP.18r12475.
Arabzadeh S, Hakkikazazi E, Shahmansouri N, Tafakhori A, Ghajar A, Jafarinia M, et al. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. J Affect Disord. 2018;235:236–41.
Domany Y, Bleich-Cohen M, Tarrasch R, Meidan R, Litvak-Lazar O, Stoppleman N, et al. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry. 2019;214:20–6.
Jafarinia M, Afarideh M, Tafakhori A, Arbabi M, Ghajar A, Noorbala AA, et al. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial. J Affect Disord. 2016;204:1–8.
Andrade C. Oral ketamine for depression, 2: practical considerations. J Clin Psychiatry. 2019;80. https://doi.org/10.4088/JCP.19f12838.
Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998;87:1186–93.
Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, et al. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in alpha7 nicotinic acetylcholine receptors. Eur J Pharmacol. 2013;698:228–34.
Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal Esketamine adjunctive to Oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75:139–48.
Paul R, Schaaff N, Padberg F, Moller HJ, Frodl T. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry. 2009;10:241–4.
Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, et al. Intravenous Esketamine in adult treatment-resistant depression: a double-blind, double-randomization, Placebo-Controlled Study. Biol Psychiatry. 2016;80:424–31.
Liu J, Ji XQ, Zhu XZ. Comparison of psychic emergence reactions after (+/−)-ketamine and (+)-ketamine in mice. Life Sci. 2006;78:1839–44.
Pfenninger EG, Durieux ME, Himmelseher S. Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology. 2002;96:357–66.
Glue P, Neehoff SM, Medlicott NJ, Gray A, Kibby G, McNaughton N. Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. J Psychopharmacol. 2018;32:663–7.
Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999;60(Suppl 22):29–34.
Yalcin I, Barrot M. The anxiodepressive comorbidity in chronic pain. Curr Opin Anaesthesiol. 2014;27:520–7.
Beard E, Shahab L, Cummings DM, Michie S, West R. New pharmacological agents to aid smoking cessation and tobacco harm reduction: what has been investigated, and what is in the pipeline? CNS Drugs. 2016;30:951–83.
Cerner Multum, Inc. Drug Interactions Checker. https://www.drugs.com/drug_interactions.html. 2000, updated 2019. Accessed 5 Mar 2019.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association Publishing; 2013.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278–96.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33.
Irwin SA, Iglewicz A, Nelesen RA, Lo JY, Carr CH, Romero SD, et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med. 2013;16:958–65.
Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry. 2010;43:33–5.
Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68:935–40.
Koo TK, Li MY. A guideline of selecting and reporting Intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155–63.
Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi HM. The inventory of depressive symptomatology (IDS). Psychol Med. 1986;26:477–86.
Guy W. ECDEU assessment manual for psychopharmacology. Rockville: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976.
Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale. Br J Psychiatry. 1995;167:99–103.
Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011;35:537–55.
Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol. 1979;47:343–52.
Andrade C. Ketamine for Depression, 6: Effects on Suicidal Ideation and Possible Use as Crisis Intervention in Patients at Suicide Risk. J Clin Psychiatry. 2018;79. https://doi.org/10.4088/JCP.18f12242.
Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175:150–8.
Williams JMG, Dritschel BH. Emotional disturbance and the specificity of autobiographical memory. Cognit Emot. 1988;22:221–34.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.
Rossell SL, Schutte MJL, Toh WL, Thomas N, Strauss C, Linszen MMJ. The questionnaire for psychotic experiences: an examination of the validity and reliability. Schizophr Bull. 2019;45:S78–87.
Stiglmayr C, Schimke P, Wagner T, Braakmann D, Schweiger U, Sipos V. Development and psychometric characteristics of the dissociation tension scale. J Pers Assess. 2010;92:269–77.
Koffel E, Watson D. Development and initial validation of the Iowa sleep disturbances inventory. Assessment. 2010;17:423–39.
Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22:343–81.
Peeters FP, Ruhe HG, Wichers M, Abidi L, Kaub K, Van der Lande HJ, et al. The Dutch measure for quantification of treatment resistance in depression (DM-TRD): an extension of the Maudsley staging method. J Affect Disord. 2016;205:365–71.
Hoekstra HA, Ormel J, De Furyt F. De NEO-PI-R/NEO-FFI; big five Persoonslijkheidsvragenlijsten. Handleiding [Manueal of the Dutch version of the NEO-PI-R/NEO-FFI]. Swets en Zeitlinger: Lisse; 1996.
Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000;31:73–86.
Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain. 1992;50:133–49.
Osman A, Kopper BA, Barrios FX, Osman JR, Wade T. The Beck anxiety inventory: reexamination of factor structure and psychometric properties. J Clin Psychol. 1997;53:7–14.
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict. 1991;86:1119–27.
Jentsch MC, Van Buel EM, Bosker FJ, Gladkevich AV, Klein HC, Oude Voshaar RC, et al. Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses. Biomark Med. 2015;9:277–97.
Bouwmans C, De Jong K, Timman R, Zijlstra-Vlasveld M, Van der Feltz-Cornelis C, Tan SS. Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P). BMC Health Serv Res. 2013;13:217–25.
Versteegh MM, Vermeulen KM, Evers SMAA, De Wit GA, Prenger R, Stolk EA. Dutch tariff for the five-level version of EQ-5D. Value Health. 2016;19:343–52.
Kanters TA, Bouwmans CAM, Van der Linden N, Tan SS, Hakkaart-van RL. Update of the Dutch manual for costing studies in health care. PLoS One. 2017;12:e0187477.
Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci. 1982;71:539–42.
Chong CC, Schug SA, Page-Sharp M, Ilett KF. Bioavailability of ketamine after Oral or sublingual administration. Pain Med. 2006;7:469.
Fanta S, Kinnunen M, Backman JT, Kalso E. Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur J Clin Pharmacol. 2015;71:441–7.
Yang C, Kobayashi S, Nakao K, Dong C, Han M, Qu Y, et al. AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-Norketamine. Biol Psychiatry. 2018;84:591–600.
Moukaddam NJ, Hirschfeld RM. Intravenous antidepressants: a review. Depress Anxiety. 2004;19:1–9.
Costi S, Soleimani L, Glasgow A, Brallier J, Spivack J, Schwartz J, et al. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. Neuropsychopharmacology. 2019. https://doi.org/10.1038/s41386-019-0365-0.
Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012;37:1526–33.
Wilkinson ST, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, et al. Cognitive behaviour therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother Psychosom. 2017;86:162–7.
Bourgon LN, Kellner CH. Relapse of depression after ECT: a review. J ECT. 2000;16:19–31.
Katz RB, Toprak M, Wilkinson ST, Sanacora G, Ostroff R. Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: a letter to the editor. Gen Hosp Psychiatry. 2018;54:62–4.
Farré M, Camí J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict. 1991;86:1601–6.
Joseph SS, Ganguli S. J&J prices ketamine-like depression treatment at $590–$885 for two doses. 2019. https://www.reuters.com/article/us-johnson-johnson-fda-pricing/jj-prices-ketamine-like-depression-treatment-at-590-885-for-two-doses-idUSKCN1QN2AX. Accessed 20 June 2019.
Aroni F, Iacovidou N, Dontas I, Pourzitaki C, Xanthos T. Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug. J Clin Pharmacol. 2009;49:957–64.
Correia-Melo FS, Leal GC, Carvalho MS, Jesus-Nunes AP, Ferreira CBN, Vieira F, et al. Comparative study of esketamine and racemic ketamine in treatment-resistant depression: protocol for a non-inferiority clinical trial. Medicine (Baltimore). 2018;97:e12414.
Centraal Bureau voor de Statistiek (CBS). Nederlanders steeds langer maar vooral zwaarder. 2012. https://www.cbs.nl/nl-nl/nieuws/2012/49/nederlanders-steeds-langer-maar-vooral-zwaarder. Accessed 3 Mar 2019.
Xu Y, Hackett M, Carter G, Loo C, Gálvez V, Glozier N, et al. Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2016;19:pyv124.
Haijen ECHM, Kaelen M, Roseman L, Timmermann C, Kettner H, Russ S, et al. Predicting responses to psychedelics: a prospective study. Front Pharmacol. 2018;9:897–917.
Mathai DS, Mathew SJ, Storch EA, Kosten TR. Revisiting the hallucinogenic potential of ketamine. 2018. https://www.psychiatrictimes.com/psychopharmacology/revisiting-hallucinogenic-potential-ketamine/page/0/1. Accessed 23 June 2019.
Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010;105:121–33.
Morgan CJ, Curran HV. Independent scientific committee on drugs. Ketamine use: a review. Addiction. 2012;107:27–38.
Wu P, Wang Q, Huang Z, Wang J, Wu Q, Lin T. Clinical staging of ketamine-associated urinary dysfunction: a strategy for assessment and treatment. World J Urol. 2016;34:1329–36.